Brief: MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
26/01/2026 11:06
Jan 26 (Reuters) - MannKind Corp MNKD.O: MANNKIND ANNOUNCES FDA APPROVAL OF UPDATED AFREZZA® LABEL PROVIDING STARTING DOSE GUIDANCE WHEN SWITCHING FROM MULTIPLE DAILY INJECTIONS (MDI) OR INSULIN PUMP MEALTIME THERAPY Source text: ID:nGNX7QDM1L Further company coverage: MNKD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children